Nactech Biotechnology Co., Ltd. (hereinafter referred to as Nactech Biotechnology Co., Ltd.) was established in 2016. With its headquarters in Taiwan as its base, the company utilizes its core competitiveness in the field of genomics and integrates a virtual team operating model, dedicating itself to the development of innovative drugs. With rich experience in new drug development, the professional team of Nactech Biotechnology Co., Ltd. screens innovative project sources from various domestic and foreign entities, including academia and research institutes, small biotechnology companies, and major international pharmaceutical companies. Through methods such as joint R&D and technology licensing, the company closely combines the capabilities of both parties to initiate drug development. It then introduces the most suitable CRO and CMO strategic partners to advance innovative drugs to the "proof of concept" (POC) stage. Subsequently, through licensing and partnering, the development of innovative drugs is handed over to the most promising development teams to conduct late-stage clinical trials, ultimately bringing the products to market.

In the development of innovative drugs, from project selection and R&D processes to strategic partnerships, Nactech Biotechnology Co., Ltd. closely combines its core competitiveness in the field of genomic science with global resources through "close cooperation" to maximize the value-added benefits of new drug development. This is also the innovative operating model of Nactech Biotechnology Co., Ltd. to create maximum value with limited resources. In 2019, Nactech Biotechnology Co., Ltd. participated in the "Satellite Base Promotion of Intelligent Robot Project" of the Central Taiwan Science Park Bureau and established a genomic drug R&D laboratory. The laboratory utilizes bioinformatics algorithms and biological structure technologies to screen and develop compounds with medical potential. This approach differs from gene therapies that act on abnormal genetic DNA, which carry the risk of damaging human genes. Since RNA plays a crucial role in gene transcription and gene regulation in nature, RNA therapeutics targeting RNA are regarded as a relatively safe and highly promising emerging therapy.

The company has currently secured investment from a listed company to produce industrial chemical antidotes, which are scheduled for market launch in 2020. Additionally, the company plans to apply for funding from the National Development Fund, aiming to accelerate the progress of R&D and commercialization. In addition, Nactech Biotechnology Co., Ltd. also has ongoing R&D projects with National Chung Hsing University, and has successfully established an industry-academia-research collaboration platform with its partner, National Chung Hsing University.